Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ritodrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.97 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.97 |
| ▸ | GALR3 | O60755 | 1/20 | 0.97 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rel-Ritodrine SCHEMBL3677546 | 1.00 | LMNA (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL3677547 | 1.00 | LMNA (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL18952960 | 1.00 | LMNA (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL122631 | 1.00 | LMNA (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL2587077 | 0.98 | LMNA (0.97) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL4430018 | 0.98 | ADRB2 (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL34194 | 0.98 | ADRB2 (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL29395182 | 0.98 | ADRB2 (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Ritodrine SCHEMBL16267904 | 0.98 | ADRB2 (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 | |
| Rel-Ritodrine SCHEMBL12959065 | 0.98 | ADRB2 (1.00) | LMNASLC6A2OPRM1HIF1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4728879-A1 | MEMORY DISORDER AMELIORATING AGENT | National University Corporation Kobe University (JP) | 2026-04-22 | — | — | EP | claimed |
| WO-2025005135-A1 | MEMORY DISORDER AMELIORATING AGENT | 国立大学法人神戸大学 | 2025-01-02 | — | — | WO | claimed |
| WO-2024029239-A1 | AFFECTIVE DISORDER AMELIORATING AGENT | 国立大学法人神戸大学 | 2024-02-08 | — | — | WO | claimed |
| WO-2022131880-A2 | PHARMACEUTICALLY STABLE SOFT CAPSULE COMPRISING TWO OR MORE DIFFERENT COMPOSITIONS | 코스맥스파마 주식회사 | 2022-06-23 | — | — | WO | claimed |
| EP-3386498-A1 | METHOD FOR MODULATING AUTOPHAGY AND APPLICATIONS THEREOF | Jawaharlal Nehru Centre For Advanced Scientific Research (IN) | 2018-10-17 | — | — | EP | claimed |
| WO-2017098467-A1 | METHOD FOR MODULATING AUTOPHAGY AND APPLICATIONS THEREOF | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH (IN) | 2017-06-15 | — | — | WO | claimed |
| EP-4728879-A1 | MEMORY DISORDER AMELIORATING AGENT | National University Corporation Kobe University (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12582687-B2 | Composition based on Crocus sativus and Cannabis sativa | ACTIV'INSIDE (FR) | 2026-03-24 | — | — | US | disclosed |
| US-12557843-B2 | Other than cannabinoids, flavonoids, and terpenes | LARSON RAYMOND LOUIS (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250108084-A1 | COMPOSITION BASED ON CROCUS SATIVUS AND CANNABIS SATIVA | ACTIV'INSIDE (FR) | 2025-04-03 | — | — | US | disclosed |
| US-20250011803-A1 | Composition and Methods for Producing Tobacco Plants and Products Having Reduced Tobacco-Specific Nitrosamines (TSNAs) | ALTRIA CLIENT SERVICES LLC (US) | 2025-01-09 | — | — | US | disclosed |
| WO-2025005135-A1 | MEMORY DISORDER AMELIORATING AGENT | 国立大学法人神戸大学 | 2025-01-02 | — | — | WO | disclosed |
| US-20240376488-A1 | TOBACCO PLANTS COMPRISING REDUCED NICOTINE AND REDUCED TOBACCO SPECIFIC NITROSAMINES | ALTRIA CLIENT SERVICES LLC (US) | 2024-11-14 | — | — | US | disclosed |
| US-20130123539-A1 | METHODS FOR PREPARING RITODRINE HYDROCHLORIDE | LUNDBECK PHARMACEUTICALS ITALY S.P.A. (IT) | 2013-05-16 | — | — | US | disclosed |
| US-20100130456-A1 | Drug Combination and Its Use in the Treatment of Muscle Loss | ACACIA PHARMA LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| EP-2155180-A2 | DRUG COMBINATION AND ITS USE IN THE TREATMENT OF MUSCLE LOSS | Acacia Pharma Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008129308-A2 | DRUG COMBINATION AND ITS USE IN THE TREATMENT OF MUSCLE LOSS | ACACIA PHARMA LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| EP-0603414-B1 | (-)-RITODRINE | MEIJI SEIKA CO (JP) | 1997-02-12 | — | — | EP | disclosed |
| US-5449694-A | Muscle relaxants for threatened premature birth and abortion; dysmenorrhea | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-09-12 | — | — | US | disclosed |
| EP-0603414-A1 | (-)-RITODRINE | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582687-B2 | Composition based on Crocus sativus and Cannabis sativa | CHRNA6, CNR2, CSNK1G2 | ADRB2 1553/4885LMNA 2027/4885SLC6A2 1378/4885 |
| US-20130123539-A1 | METHODS FOR PREPARING RITODRINE HYDROCHLORIDE | COMT, ADRA2C, ADRA1D | ADRB2 76/4885LMNA 1174/4885SLC6A2 110/4885 |
| US-12557843-B2 | Other than cannabinoids, flavonoids, and terpenes | CCT5, CNR2, CPNE4 | ADRB2 439/4885LMNA 2022/4885SLC6A2 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.